Huabio - Model GARS -SC0651 ET1610-67 - Recombinant Rabbit Monoclonal Antibody

Because recombinant antibody production involves sequencing the antibody light and heavy chains, recombinant antibody production allows researchers more control over the antigen. In contrast, hybridoma-based systems for producing monoclonal antibodies are subject to genetic drift and instability, increasing the potential for lot-to-lot variability. Since rAbs are defined by the sequences that encode them, they are more reliable and provide more reproducible results than mAbs. By adjusting experimental conditions, researchers can easily favor the isolation of antibodies against antigens.

In vitro methods for producing antibodies are amenable to large-scale production, meaning antibody availability is unlikely to become a limiting factor. Recombinant antibodies can be produced in weeks as opposed to months. Moreover, since the recombinant antibody sequence is known, continuity of supply is assured. This means antibody expression can be carried out at any scale with guaranteed long-term supply giving you added peace of mind and continuity for projects of all sizes, making recombinant antibodies a great solution for long-term studies.